1400 related items for PubMed ID: 17000959
1. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
[Abstract] [Full Text] [Related]
2. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
Cohen BA, Rivera VM.
Curr Med Res Opin; 2010 Apr 26; 26(4):827-38. PubMed ID: 20121658
[Abstract] [Full Text] [Related]
3.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
4. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR, Panitch HS.
Clin Ther; 2007 Sep 26; 29(9):2031-48. PubMed ID: 18035202
[Abstract] [Full Text] [Related]
5. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
Mult Scler; 2010 Jul 26; 16(7):848-54. PubMed ID: 20488825
[Abstract] [Full Text] [Related]
6. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
Mult Scler; 2009 Aug 26; 15(8):965-76. PubMed ID: 19465443
[Abstract] [Full Text] [Related]
7.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
8. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G, EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group, University of British Columbia MS/MRI Research Group.
Arch Neurol; 2005 May 26; 62(5):785-92. PubMed ID: 15883267
[Abstract] [Full Text] [Related]
9. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
Cocco E, Marchi P, Floris G, Mascia MG, Deriu M, Sirca A, Mamusa E, Lai M, Mura M, Mallarini G, Marrosu MG.
Funct Neurol; 2006 May 26; 21(3):145-9. PubMed ID: 17049133
[Abstract] [Full Text] [Related]
10. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
Neurol Sci; 2005 Dec 26; 26 Suppl 4():S174-8. PubMed ID: 16388353
[Abstract] [Full Text] [Related]
11. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study.
Oger J, Francis G, Chang P, PRISMS Study Group.
J Neurol Sci; 2005 Oct 15; 237(1-2):45-52. PubMed ID: 16026803
[Abstract] [Full Text] [Related]
12. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L.
J Neurol Sci; 2004 Jul 15; 222(1-2):13-9. PubMed ID: 15240190
[Abstract] [Full Text] [Related]
13. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
[Abstract] [Full Text] [Related]
14. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A, Durastanti V, Gasperini C, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E, CoSa Study Group.
Clin Neuropharmacol; 2008 Feb 10; 31(3):167-72. PubMed ID: 18520983
[Abstract] [Full Text] [Related]
15. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
Murray TJ.
Curr Med Res Opin; 2004 Jan 10; 20(1):25-30. PubMed ID: 14741068
[Abstract] [Full Text] [Related]
16.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
18. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
Ann Neurol; 1996 Mar 10; 39(3):285-94. PubMed ID: 8602746
[Abstract] [Full Text] [Related]
19.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
Page: [Next] [New Search]
